Management strategies in pancreatic cancer
| العنوان: | Management strategies in pancreatic cancer |
|---|---|
| المؤلفون: | Amanda F. Baker, Tomislav Dragovich, Christopher J Campen |
| المصدر: | American Journal of Health-System Pharmacy. 68:573-584 |
| بيانات النشر: | Oxford University Press (OUP), 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Pharmacology, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, Health Policy, medicine.medical_treatment, Disease Management, Cancer, Disease, medicine.disease, Gemcitabine, Pancreatic Neoplasms, Internal medicine, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, medicine, Adjuvant therapy, Animals, Humans, Adenocarcinoma, business, Adverse effect, medicine.drug |
| الوصف: | Purpose Current first-line and adjuvant chemotherapeutic strategies for management of patients with pancreatic cancer are reviewed. Summary Pancreatic adenocarcinoma is the 10th most prevalent cancer and the fourth most common cause of cancer deaths in the United States. More than 80% of patients with pancreatic cancer are diagnosed with locally advanced or metastatic disease and are not candidates for surgery; these patients often require multimodal treatment. The most widely used chemotherapy for such patients, as well as patients requiring adjuvant therapy after surgery, is gemcitabine or gemcitabine-based chemotherapy. All current chemotherapies for pancreatic cancer are associated with dose-limiting hematologic toxicity and other adverse effects that require ongoing monitoring and dosage adjustment to balance the benefits and risks of treatment. Pharmacists can play an important role in monitoring and providing drug information and guidance to patients and oncologists. Current investigational strategies include efforts to improve chemotherapy response rates and outcomes through modulation of cell signaling pathways and use of nanotechnology to improve drug delivery. Conclusion Current management of pancreatic cancer is multifaceted, involving anticancer therapy, supportive care, and toxicity management. Standard systemic therapy with gemcitabine as a single agent or in combination with other cytotoxic agents provides modest benefits in terms of response and symptom control. |
| تدمد: | 1535-2900 1079-2082 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84915d4f30ee5567af87767df9cd31dd https://doi.org/10.2146/ajhp100254 |
| رقم الأكسشن: | edsair.doi.dedup.....84915d4f30ee5567af87767df9cd31dd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15352900 10792082 |
|---|